Canarian startup Bioreplica revolutionises spine surgery with biomimetic implant

For decades, the Canary Islands have been synonymous with sun, sea, and a service economy built almost entirely around tourism. But quietly, a different kind of industry has been taking root in the archipelago — one that deals in titanium, patents, and the intricate biomechanics of the human body. At the forefront of this shift is Bioreplica, a med-tech startup founded in Las Palmas de Gran Canaria that is developing a new generation of spinal implants designed to move the way a real vertebra does.

The company was born at the University of Las Palmas de Gran Canaria (ULPGC), where founder Rodrigo de Pablos Almazán studied physiotherapy before launching the project. After finishing his degree and gaining hands-on clinical experience, he spotted a recurring problem: existing vertebral prostheses were often too rigid, failing to replicate the subtle, load-distributing movements of a healthy spine. That observation became the seed for BioVert Replica, a biomimetic implant that the company says protects the spinal cord while adapting far better to natural spinal mechanics.

From a physio's insight to an international award-winner

Rodrigo de Pablos didn't take the typical startup founder's path. There was no business school background, no Silicon Valley network. Instead, he brought something arguably more valuable: a deep, practical understanding of how the human spine actually behaves under stress, gained from treating patients day after day. That clinical lens shaped the entire design philosophy behind BioVert Replica.

The implant is machined from titanium but incorporates an internal suspension system — a feature that sets it apart from conventional, monolithic prostheses. The idea is to more faithfully reproduce both the shape and the biomechanical behaviour of a natural vertebra. In theory, this means better load transmission across the spinal column, improved stability, and potentially fewer long-term complications for patients. It is important to note that these are the company's stated design aims; independent clinical outcome data is not yet publicly available, as the device is still moving through the necessary regulatory and study phases.

What is already clear, however, is that the wider world has taken notice. The first BioVert Replica design has been patented, and the startup has collected a string of international accolades that would be impressive for any company, let alone one from a region not traditionally known for deep-tech manufacturing. At the Geneva inventions convention, Bioreplica walked away with a gold medal with a special mention in the field of medicine, as well as a WIPO gold medal from the World Intellectual Property Organization. Closer to home, the project also received the Francisco García Cabrerizo award, a respected Spanish prize for young researchers and innovators.

Why a Canarian med-tech startup matters

It is easy to underestimate what it means for a company like Bioreplica to emerge from Gran Canaria. The Canarian economy has long been dominated by hospitality, construction, and retail — sectors that, while vital, leave the islands vulnerable to external shocks, as the pandemic made painfully clear. In recent years, public institutions and private investors have been pushing hard for diversification into knowledge-based industries. Med-tech, in particular, has been identified as a promising niche, with regional press estimating the sector's annual turnover at around €20 million and active projects worth roughly €18 million across the archipelago.

Bioreplica fits squarely into that narrative. It is a high-value technology company created entirely within the islands, drawing on local university talent and aiming to compete in a global market where precision engineering and regulatory expertise are the price of entry. The company's address on Avenida José Mesa y López in the heart of Las Palmas places it firmly in the island's capital, a city better known for its port and its beaches than for spinal implant R&D. That contrast is precisely the point.

The road ahead: funding, studies, and regulatory hurdles

For all the awards and promising design work, Bioreplica is still a startup navigating the long, expensive path to market that defines the medical device industry. According to a separate startup profile, the company had raised around $650,000 and was actively seeking additional capital. The funds are earmarked for two critical, resource-intensive phases: clinical studies to validate the implant's performance in real-world settings, and the regulatory approvals needed to sell a spinal prosthesis in major markets like the European Union and the United States.

The company has also stated it is looking for collaborators and investors, though no specific hospital partnerships have been publicly confirmed in the reporting available. This is not unusual for a device at this stage — clinical collaborations are often announced only once formal agreements are signed and patient recruitment begins. What matters for now is that Bioreplica has moved beyond the concept phase, secured intellectual property protection, and attracted enough early-stage funding to keep development moving forward.

Rodrigo de Pablos himself has spoken publicly about the broader trends driving demand for better spinal solutions. In a recent radio interview, he pointed to rising sedentary lifestyles as a factor increasing the prevalence of spinal conditions, arguing that the market needs new approaches that go beyond simply fusing vertebrae or inserting rigid cages. His background as a physiotherapist gives that argument a credibility that pure engineering pitches sometimes lack — he has seen the limitations of current options from the patient's side of the table.

Canarias as a quiet med-tech hub

Bioreplica does not exist in a vacuum. Across the islands, a small but growing cluster of companies and research groups is working at the intersection of medicine, materials science, and advanced manufacturing. 3D printing of anatomical models for surgical planning, custom implants, and rehabilitation technologies are all areas where Canarian teams have built expertise, often in collaboration with the ULPGC and other regional institutions.

What makes Bioreplica stand out is the combination of a patented, award-winning product and a founder story that feels genuinely rooted in clinical need rather than a technology push. The company is not selling a 3D-printing service or a software platform — it is developing a specific, regulated medical device for a defined surgical application. That focus, coupled with the early international recognition, gives it a profile that could attract the kind of venture capital that has historically flowed to mainland Spanish hubs like Barcelona and Madrid.

Whether Bioreplica becomes a flagship for Canarian med-tech will depend on the clinical data that emerges from the next phase of development. But the pieces are in place: a credible founder, a protected design, seed funding, and a growing awareness that the islands can produce more than just great bananas and holiday memories.